China Universal Asset Management Co., Ltd. Esperion Therapeutics, Inc. Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$0.96 - $1.79 $1,446 - $2,697	1,507 Added 121.43%	2,748 $2,000
Q3 2023 Oct 30, 2023	BUY	$0.96 - $1.79 $1,446 - $2,697	1,507 Added 121.43%	2,748 $3,000
Q2 2023 May 21, 2024	BUY	$1.2 - $1.76 $243 - $357	203 Added 19.56%	1,241 $1,000
Q2 2023 Jul 27, 2023	BUY	$1.2 - $1.76 $243 - $357	203 Added 19.56%	1,241 $2,000
Q1 2023 May 21, 2024	BUY	$1.46 - $7.3 $421 - $2,109	289 Added 38.58%	1,038 $1,000
Q1 2023 Apr 27, 2023	BUY	$1.46 - $7.3 $421 - $2,109	289 Added 38.58%	1,038 $2,000
Q4 2022 May 21, 2024	BUY	$5.09 - $8.5 $3,812 - $6,366	749 New	749 $4,000
Q4 2022 Jan 31, 2023	BUY	$5.09 - $8.5 $641 - $1,071	126 Added 20.22%	749 $5,000
Q3 2022 Oct 21, 2022	BUY	$5.45 - $8.13 $3,395 - $5,064	623 New	623 $4,000

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account